These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 15017333)

  • 1. Mutations in exon 14 of dihydropyrimidine dehydrogenase and 5-Fluorouracil toxicity in Portuguese colorectal cancer patients.
    Salgueiro N; Veiga I; Fragoso M; Sousa O; Costa N; Pellon ML; Sanches E; dos Santos JG; Teixeira MR; Castedo S
    Genet Med; 2004; 6(2):102-7. PubMed ID: 15017333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment.
    Amstutz U; Farese S; Aebi S; Largiadèr CR
    Pharmacogenomics; 2009 Jun; 10(6):931-44. PubMed ID: 19530960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-Fluorouracil toxicity-attributable IVS14 + 1G > A mutation of the dihydropyrimidine dehydrogenase gene in Polish colorectal cancer patients.
    Sulzyc-Bielicka V; Bińczak-Kuleta A; Pioch W; Kładny J; Gziut K; Bielicki D; Ciechanowicz A
    Pharmacol Rep; 2008; 60(2):238-42. PubMed ID: 18443386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency.
    van Kuilenburg AB; Muller EW; Haasjes J; Meinsma R; Zoetekouw L; Waterham HR; Baas F; Richel DJ; van Gennip AH
    Clin Cancer Res; 2001 May; 7(5):1149-53. PubMed ID: 11350878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two cases of 5-fluorouracil toxicity linked with gene variants in the DPYD gene.
    Ofverholm A; Arkblad E; Skrtic S; Albertsson P; Shubbar E; Enerbäck C
    Clin Biochem; 2010 Feb; 43(3):331-4. PubMed ID: 19822137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absence of large intragenic rearrangements in the DPYD gene in a large cohort of colorectal cancer patients treated with 5-FU-based chemotherapy.
    Paré L; Paez D; Salazar J; Del Rio E; Tizzano E; Marcuello E; Baiget M
    Br J Clin Pharmacol; 2010 Aug; 70(2):268-72. PubMed ID: 20653680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil.
    van Kuilenburg AB
    Eur J Cancer; 2004 May; 40(7):939-50. PubMed ID: 15093568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation.
    Van Kuilenburg AB; Meinsma R; Zoetekouw L; Van Gennip AH
    Int J Cancer; 2002 Sep; 101(3):253-8. PubMed ID: 12209976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutational analysis of the human dihydropyrimidine dehydrogenase gene by denaturing high-performance liquid chromatography.
    Fischer J; Schwab M; Eichelbaum M; Zanger UM
    Genet Test; 2003; 7(2):97-105. PubMed ID: 12885330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemotherapy.
    Kleibl Z; Fidlerova J; Kleiblova P; Kormunda S; Bilek M; Bouskova K; Sevcik J; Novotny J
    Neoplasma; 2009; 56(4):303-16. PubMed ID: 19473056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene.
    van Kuilenburg AB; Haasjes J; Richel DJ; Zoetekouw L; Van Lenthe H; De Abreu RA; Maring JG; Vreken P; van Gennip AH
    Clin Cancer Res; 2000 Dec; 6(12):4705-12. PubMed ID: 11156223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe fluoropyrimidine toxicity due to novel and rare DPYD missense mutations, deletion and genomic amplification affecting DPD activity and mRNA splicing.
    van Kuilenburg AB; Meijer J; Maurer D; Dobritzsch D; Meinsma R; Los M; Knegt LC; Zoetekouw L; Jansen RL; Dezentjé V; van Huis-Tanja LH; van Kampen RJ; Hertz JM; Hennekam RC
    Biochim Biophys Acta Mol Basis Dis; 2017 Mar; 1863(3):721-730. PubMed ID: 28024938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variants in the dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase and thymidylate synthase genes predict early toxicity of 5-fluorouracil in colorectal cancer patients.
    Kristensen MH; Pedersen PL; Melsen GV; Ellehauge J; Mejer J
    J Int Med Res; 2010; 38(3):870-83. PubMed ID: 20819423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity.
    van Kuilenburg AB; Meijer J; Mul AN; Meinsma R; Schmid V; Dobritzsch D; Hennekam RC; Mannens MM; Kiechle M; Etienne-Grimaldi MC; Klümpen HJ; Maring JG; Derleyn VA; Maartense E; Milano G; Vijzelaar R; Gross E
    Hum Genet; 2010 Nov; 128(5):529-38. PubMed ID: 20803296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity.
    Van Kuilenburg AB; Meinsma R; Zoetekouw L; Van Gennip AH
    Pharmacogenetics; 2002 Oct; 12(7):555-8. PubMed ID: 12360106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation of IVS14+ 1G > A polymorphism of DPYD gene in a group of Turkish patients with colorectal cancer.
    Uzunkoy A; Dilmec F; Ozgonul A; van Kuilenburg AB; Akkafa F
    Anticancer Res; 2007; 27(6B):3899-902. PubMed ID: 18225548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy.
    Amstutz U; Farese S; Aebi S; Largiadèr CR
    J Exp Clin Cancer Res; 2008 Oct; 27(1):54. PubMed ID: 18937829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a novel mutation in the dihydropyrimidine dehydrogenase gene in a patient with a lethal outcome following 5-fluorouracil administration and the determination of its frequency in a population of 500 patients with colorectal carcinoma.
    Morel A; Boisdron-Celle M; Fey L; Lainé-Cessac P; Gamelin E
    Clin Biochem; 2007 Jan; 40(1-2):11-7. PubMed ID: 17046731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer.
    Deenen MJ; Tol J; Burylo AM; Doodeman VD; de Boer A; Vincent A; Guchelaar HJ; Smits PH; Beijnen JH; Punt CJ; Schellens JH; Cats A
    Clin Cancer Res; 2011 May; 17(10):3455-68. PubMed ID: 21498394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls.
    Raida M; Schwabe W; Häusler P; Van Kuilenburg AB; Van Gennip AH; Behnke D; Höffken K
    Clin Cancer Res; 2001 Sep; 7(9):2832-9. PubMed ID: 11555601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.